替加环素对ICU多重耐药菌感染患者免疫功能的影响及疗效分析

Effect of Tigecycline on Immune Function in Patients with Multidrug-resistant ICU Infection and its Therapeutic Effect

目的分析替加环素对ICU多重耐药菌感染患者进行治疗对患者免疫功能的影响和临床效果。方法将2018年4月至2019年4月到我院ICU实施治疗的96例多重耐药菌感染患者随机分为观察组和对照组,每组48例。观察组以头孢哌酮舒巴坦联合替加环素治疗,对照组常规实施头孢哌酮舒巴坦治疗。比较两组患者经不同治疗后的效果。结果①观察组[93.75%(45/48)]的治疗总有效率明显高于对照组[75.00%(36/48)],有统计学差异(P<0.05)。②观察组[4.17%(2/48)]的不良反应发生率和对照组[6.25%(3/48)]相比无差异,差异无统计学意义(P>0.05)。③观察组治疗后的IgA、IgM、IgG、NK细胞等改善明显优于对照组,有统计学差异(P<0.05)。结论头孢哌酮舒巴坦联合替加环素对ICU多重耐药菌感染的患者进行治疗能在确保安全的前提下提升疗效,改善免疫功能,值得推荐。

Objective To analyze the effect and clinical effect of tigecycline on the immune function of patients with multi-drug resistant bacteria infection in ICU.Methods From April 2018 to April 2019,96 patients with multi-drug resistant bacteria infection who were treated in the ICU of our hospital were randomly divided into observation group and control group,with 48 cases in each.The observation group was treated with cefoperazone and sulbactam combined with tigecycline,and the control group was routinely treated with cefoperazone and sulbactam.Compare the effects of two groups of patients after different treatments.Results(1)The total effective rate of treatment in the observation group[93.75%(45/48)]was significantly higher than that of the control group[75.00%(36/48)],which was statistically different(P<0.05).(2)The observation group[4.17%(2/48)]there was no difference in the incidence of adverse reactions compared with the control group[6.25%(3/48)],and the difference was no statistically significant(P>0.05).(3)The improvement of IgA,IgM,IgG,NK cells in the observation group after treatment was significantly better than that of the control group,with statistical differences(P<0.05).Conclusion Cefoperazone and sulbactam combined with tigecycline for the treatment of ICU patients with multi-drug resistant bacteria infection can improve the efficacy and improve the immune function under the premise of ensuring safety,and it is worth recommending.